Phase 1b was an open-label , dose de-escalation study to identify a safe dose of rilotumumab ( initial dose 15 mg/kg intravenously on day 1 ) plus ECX ( epirubicin 50 mg/m ( 2 ) intravenously on day 1 , cisplatin 60 mg/m ( 2 ) intravenously on day 1 , capecitabine 625 mg/m ( 2 ) twice a day orally on days 1-21 , respectively ) , administered every 3 weeks .